Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that CARE Ratings Limited ('CARE') has vide its letter dated 29th October, 2018 assigned us the following credit rating: 1. Assigned the credit rating of 'CARE A1+' for Commercial Paper (CP) issue of upto Rs. 500 Crores. Completion Of US FDA Inspection Of General Oral Solid Formulation Facility
We would like to inform that the United States Food and Drug Administration (US FDA) has completed an inspection of its general oral solid formulation facility at Panelav, Gujarat, India. This was a scheduled pre-approval inspection carried out from 22nd October, 2018 to 26th October, 2018 and at the end of the inspection, the US FDA issued a Form 483 with four procedural observations.... Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 24th October, 2018. We request you to kindly take the same on record. Alembic Pharmaceuticals Q2 net profit rises 62% to Rs 2.07 billion
The revenues grew 43 per cent to Rs 11.27 billion Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2018.
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2018. We enclose herewith the following: a) (i) Consolidated Unaudited Financial Results for the quarter and half year ended on 30th September, 2018.... Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has successfully cleared its first United States Food and Drugs Administration (USFDA) inspection of its new formulation manufacturing facility located at Karakhadi, Gujarat, India; without any observations.... Alembic Pharma gets USFDA nod diabetes drug
Alembic Pharmaceuticals on Tuesday informed the exchanges that it has received tentative nod from the US health regulator for its Alogliptin tablets u Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Alogliptin Tablets, 6.25 mg, 12.5 mg and 25 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 22nd October, 2018 as per the enclosed details. Kindly take the same on record. Shareholding for the Period Ended September 30, 2018
Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click here